-
1.发明申请SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION 审中-公开哌拉西汀拮抗剂的持续释放片剂配方和具有增强的内分泌溶解的5-HT1A受体的激动剂公开(公告)号：US20080226714A1
公开(公告)日：2008-09-18
申请号：US12032003
申请日：2008-02-15
IPC分类号： A61K31/496 , A61K9/22
CPC分类号： A61K9/2054 , A61K9/2013 , A61K31/496
摘要： The present invention relates to sustained-release tablet formulations of piperazine-piperidine compounds, which can be useful in treating central nervous system disorders; to processes for their preparation; and to methods of using them.
摘要翻译： 本发明涉及哌嗪 - 哌啶化合物的缓释片剂，其可用于治疗中枢神经系统疾病; 进行准备; 以及使用它们的方法。
-
公开(公告)号：US20110111018A1
公开(公告)日：2011-05-12
申请号：US12940808
申请日：2010-11-05
申请人： Muhammad Ashraf , Mainuddin Mahmud , Chimanlall Goolcharran , Krishnendu Ghosh , Arwinder Singh Nagi
发明人： Muhammad Ashraf , Mainuddin Mahmud , Chimanlall Goolcharran , Krishnendu Ghosh , Arwinder Singh Nagi
IPC分类号： A61K9/48 , A61K31/4709 , A61P35/00
CPC分类号： A61K9/28 , A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/284 , A61K31/4709
摘要： The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets.
摘要翻译： 本发明提供了包含马来酸奈替尼的包衣片剂，以及制备这种包衣片剂的改进方法。
-
公开(公告)号：US08518446B2
公开(公告)日：2013-08-27
申请号：US12940808
申请日：2010-11-05
申请人： Muhammad Ashraf , Mainuddin Mahmud , Chimanlall Goolcharran , Krishnendu Ghosh , Arwinder Singh Nagi
发明人： Muhammad Ashraf , Mainuddin Mahmud , Chimanlall Goolcharran , Krishnendu Ghosh , Arwinder Singh Nagi
IPC分类号： A61K9/16
CPC分类号： A61K9/28 , A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/284 , A61K31/4709
摘要： The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets.
摘要翻译： 本发明提供了包含马来酸奈替尼的包衣片剂，以及制备这种包衣片剂的改进方法。
-
公开(公告)号：US20060040852A1
公开(公告)日：2006-02-23
申请号：US11205935
申请日：2005-08-17
IPC分类号： A61K38/17
CPC分类号： A61K9/0019 , A61K9/19 , A61K38/1709 , A61K38/2006 , A61K47/10 , A61K47/183 , A61K47/26 , C07K14/545
摘要： Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26. Most preferably, the fusion protein has the sequence of SEQ ID NO:10.
摘要翻译： 提供白细胞介素-1（IL-1）拮抗剂的制剂，包括预先冻干的制剂，重构的冻干制剂和稳定的液体制剂。 优选地，IL-1拮抗剂是由两个融合蛋白的二聚体组成的IL-1捕获物，其具有选自SEQ ID NO：2,4,6,8,10,12,14， 16,18,20,22,24和26.最优选地，融合蛋白具有SEQ ID NO：10的序列。
-
公开(公告)号：US07572893B2
公开(公告)日：2009-08-11
申请号：US11750613
申请日：2007-05-18
IPC分类号： A61K36/20 , A61K47/48 , C07K14/475
CPC分类号： A61K38/1709 , A61K9/0019 , A61K9/19 , A61K38/1793 , A61K38/2006 , A61K47/183 , A61K47/26
摘要： Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 10.
摘要翻译： 提供白细胞介素-1（IL-1）拮抗剂的制剂，包括预先冻干的制剂，重构的冻干制剂和稳定的液体制剂。 优选地，IL-1拮抗剂是由具有选自SEQ ID NO：10的氨基酸序列的两种融合蛋白的二聚体组成的IL-1捕获物。
-
公开(公告)号：US20080188817A1
公开(公告)日：2008-08-07
申请号：US12048717
申请日：2008-03-14
CPC分类号： A61K9/19 , A61K9/0019 , A61K38/1793 , A61K38/2006 , A61K47/183 , A61K47/26
摘要： Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion proteins having an amino acid sequence of SEQ ID NO: 10. Stable liquid formulations made with and without sodium chloride, and made with phosphate or histidine buffer, are provided.
摘要翻译： 提供白细胞介素-1（IL-1）拮抗剂的制剂，包括预先冻干的制剂，重构的冻干制剂和稳定的液体制剂。 优选地，IL-1拮抗剂是由具有SEQ ID NO：10的氨基酸序列的两种融合蛋白的二聚体组成的IL-1捕获物。用和不用氯化钠制成并用磷酸盐或组氨酸缓冲液 ，提供。
-
公开(公告)号：US07655758B2
公开(公告)日：2010-02-02
申请号：US12048717
申请日：2008-03-14
IPC分类号： A61K36/20 , A61K47/48 , C07K14/475
CPC分类号： A61K9/19 , A61K9/0019 , A61K38/1793 , A61K38/2006 , A61K47/183 , A61K47/26
摘要： Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion proteins having an amino acid sequence of SEQ ID NO: 10. Stable liquid formulations made with and without sodium chloride, and made with phosphate or histidine buffer, are provided.
摘要翻译： 提供白细胞介素-1（IL-1）拮抗剂的制剂，包括预先冻干的制剂，重构的冻干制剂和稳定的液体制剂。 优选地，IL-1拮抗剂是由具有SEQ ID NO：10的氨基酸序列的两种融合蛋白的二聚体组成的IL-1捕获物。用和不用氯化钠制成并用磷酸盐或组氨酸缓冲液 ，提供。
-
公开(公告)号：US07365165B2
公开(公告)日：2008-04-29
申请号：US11205935
申请日：2005-08-17
IPC分类号： A61K38/20 , A61K47/48 , C07K14/475
CPC分类号： A61K9/0019 , A61K9/19 , A61K38/1709 , A61K38/2006 , A61K47/10 , A61K47/183 , A61K47/26 , C07K14/545
摘要： Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26. Most preferably, the fusion protein has the sequence of SEQ ID NO:10.
摘要翻译： 提供白细胞介素-1（IL-1）拮抗剂的制剂，包括预冻干制剂，重构的冻干制剂和稳定的液体制剂。 优选地，IL-1拮抗剂是由具有选自SEQ ID NO：2,4,6,8,10,12,14， 16,18,20,22,24和26.最优选地，融合蛋白具有SEQ ID NO：10的序列。
-
公开(公告)号：US20080015148A1
公开(公告)日：2008-01-17
申请号：US11750613
申请日：2007-05-18
CPC分类号： A61K38/1709 , A61K9/0019 , A61K9/19 , A61K38/1793 , A61K38/2006 , A61K47/183 , A61K47/26
摘要： Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 10.
摘要翻译： 提供白细胞介素-1（IL-1）拮抗剂的制剂，包括预先冻干的制剂，重构的冻干制剂和稳定的液体制剂。 优选地，IL-1拮抗剂是由具有选自SEQ ID NO：10的氨基酸序列的两种融合蛋白的二聚体组成的IL-1捕获物。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.018 秒)
